Gastrointestinal Stromal Tumor
📧 Sign up to get email alerts when something new happens for Gastrointestinal Stromal Tumor.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Qinlock (ripretinib) — Deciphera Pharmaceuticals (Netherlands) B.V.
Qinlock (ripretinib) has been authorised in the EU for gastrointestinal stromal tumors, with orphan medicinal product designation.
-
EMA approval · 2026-08-04EMA Authorised: Qinlock (ripretinib) — Deciphera Pharmaceuticals (Netherlands) B.V.
Qinlock (ripretinib) has been authorised in the EU for gastrointestinal stromal tumors (GIST).
-
FDA approval · 2026-04-06FDA Approved: IMATINIB MESYLATE — Supplemental Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' supplemental application for Imatinib Mesylate (ANDA 212773), approving a generic version of the cancer…
-
EMA approval · 2026-02-11EMA Authorised: Qinlock (ripretinib) — Deciphera Pharmaceuticals (Netherlands) B.V.
The EMA has authorised Qinlock (ripretinib) for use in adults with gastrointestinal stromal tumors, and the medicine carries orphan designat…
-
EMA approval · 2026-01-09EMA Authorised: Ayvakyt (avapritinib) — Blueprint Medicines (Netherlands) B.V.
The European Medicines Agency authorised Ayvakyt (avapritinib) for gastrointestinal stromal tumors with conditional approval and orphan desi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-12-04EMA Authorised: Sunitinib Accord (sunitinib) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Sunitinib Accord for the treatment of gastrointestinal stromal tumors, renal cell carcinoma, and ne…
-
EMA approval · 2025-11-12EMA Authorised: Glivec (imatinib) — Novartis Europharm Limited
The European Medicines Agency authorised Glivec (imatinib) for multiple indications, including precursor cell lymphoblastic leukemia-lymphom…
-
FDA approval · 2025-05-06FDA Approved: QINLOCK — Supplemental Application (Deciphera Pharmaceuticals, LLC)
FDA approved a supplemental application for QINLOCK (ripretinib) submitted by Deciphera Pharmaceuticals, LLC.
-
FDA approval · 2025-04-14FDA Approved: IMATINIB MESYLATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' imatinib mesylate as an original (ANDA) generic product.
-
FDA approval · 2025-03-20FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for imatinib mesylate (Teva) under an ANDA, authorizing continued regulatory approval for this gener…
-
EMA approval · 2025-03-10EMA Authorised: Sutent (sunitinib) — Pfizer Limited
Sutent (sunitinib) has been authorised by the EMA with indications for gastrointestinal stromal tumor, renal cell carcinoma, and neuroendocr…
-
FDA approval · 2025-02-14FDA Approved: SUNITINIB MALATE — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved an original generic application for sunitinib malate from Novadoz Pharmaceuticals LLC. This approval provides a generic opt…
-
FDA approval · 2025-01-08FDA Approved: IMATINIB MESYLATE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental ANDA for Imatinib Mesylate (Chartwell RX, LLC), enabling marketing of a generic version of the cancer drug.
-
FDA approval · 2024-12-09FDA Approved: IMATINIB MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for imatinib mesylate from Mylan Pharmaceuticals, effectively authorizing a supplemental approva…
-
FDA approval · 2024-11-22FDA Approved: IMKELDI — Original Application (Shorla Oncology Inc.,)
FDA approved IMKELDI (imatinib oral) under an original NDA from Shorla Oncology, authorizing a new imatinib product for several cancers incl…
-
FDA approval · 2024-03-01FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis Pharmaceuticals Corporation. This action confi…
-
FDA approval · 2024-01-05FDA Approved: IMATINIB MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application from Mylan Pharmaceuticals for imatinib mesylate, enabling a generic version to be marketed under AN…
-
FDA approval · 2023-08-21FDA Approved: SUNITINIB MALATE — Supplemental Application (NorthStar RxLLC)
The FDA approved a supplemental application for SUNITINIB MALATE (sunitinib malate) filed by NorthStar RxLLC.
-
FDA approval · 2023-08-21FDA Approved: SUNITINIB MALATE — Original Application (Novugen Pharma (USA) LLC.)
FDA approves a generic version of sunitinib malate from Novugen Pharma (USA) LLC under an Original Application (ANDA 218012).
-
FDA approval · 2023-08-16FDA Approved: IMATINIB — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for Imatinib from Dr. Reddy's Laboratories Inc, resulting in regulatory approval for a change to the…
-
FDA approval · 2023-03-09FDA Approved: AYVAKIT — Supplemental Application (Blueprint Medicines Corporation)
FDA approved a supplemental application for AYVAKIT (avapritinib) from Blueprint Medicines Corporation to update the product label (includin…
-
FDA approval · 2023-01-31FDA Approved: IMATINIB MESYLATE — Supplemental Application (BluePoint Laboratories)
FDA approves a supplemental application for Imatinib Mesylate from BluePoint Laboratories under an ANDA, confirming approval of a generic pr…
-
FDA approval · 2022-12-29FDA Approved: QINLOCK — Supplemental Application (Deciphera Pharmaceuticals, LLC)
FDA approved a supplemental application for QINLOCK (ripretinib) submitted by Deciphera Pharmaceuticals, LLC.
-
FDA approval · 2022-06-21FDA Approved: IMATINIB MESYLATE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved an original application for imatinib mesylate (Upsher-Smith Laboratories) as a generic product. The approval supports its use f…
-
FDA approval · 2022-04-11FDA Approved: SUNITINIB MALATE — Original Application (Dr.Reddys Laboratories Inc)
FDA approved a generic version of sunitinib malate (SUNITINIB MALATE) from Dr. Reddy's Laboratories Inc under Original Application.